TOP - ASH 2015 - Multiple Myeloma

A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis.
This phase 3 study demonstrated that the all-oral therapy of ixazomib in combination with lenalidomide/dexamethasone significantly increased median PFS without a substantial increase in overall toxicity. A similar benefit was noted in patients with high-risk cytogenetics.
Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant.
The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM).
A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response.
The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study.
Investigators examined the safety and efficacy of the combination of lenalidomide/ixazomib as a maintenance therapy after ASCT in a single-arm phase 2 study. Favorable results of this combination may warrant additional examination in a phase 3 study.
Results of a randomized, phase 2 study to determine the confirmed overall response rate in patients treated with ixazomib, an orally bioavailable proteasome inhibitor, for patients with relapsed multiple myeloma not refractory to bortezomib.
The ENDEAVOR study demonstrated that carfilzomib plus dexamethasone showed a significant improvement in median progression-free survival compared with bortezomib plus dexamethasone. This update examines outcomes in patients in high-risk cytogenetic subgroups.
Using a combined analysis of 2 DARA clinical studies, researchers assessed the overall response rates and clinical activity of a 16-mg/kg infusion for the treatment of relapsed and refractory multiple myeloma in heavily treated patients.
Page 2 of 3
Results 11 - 20 of 23